INDV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Indivior Pharmaceuticals, Inc (INDV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive financial growth, bullish technical indicators, and favorable analyst ratings with increased price targets. Despite the lack of recent news or congress trading data, the overall sentiment and data suggest a solid entry point for long-term investment.
The technical indicators for INDV are bullish. The MACD is above 0 and positively expanding, indicating upward momentum. The moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), and the RSI is neutral at 52.701, suggesting no overbought or oversold conditions. Key support is at 33.385, and resistance is at 35.242, with the current price near the pivot level of 34.313.
Analyst upgrades with increased price targets: Northland raised the target to $50, and Morgan Stanley raised it to $
Strong financial performance in Q3 2025, with revenue up 2.28% YoY, net income up 90.91% YoY, and EPS up 94.12% YoY.
Bullish technical indicators and positive MACD expansion.
Gross margin dropped by -6.28% YoY in Q3
Lack of recent news or significant trading trends from hedge funds or insiders.
Stock trend analysis indicates a potential short-term decline of -0.96% in the next day and -2.42% in the next month.
In Q3 2025, Indivior's revenue increased by 2.28% YoY to $314 million. Net income surged by 90.91% YoY to $42 million, and EPS rose by 94.12% YoY to 0.33. However, the gross margin declined by -6.28% YoY to 73.57%. Overall, the financial performance demonstrates strong growth in profitability despite a slight dip in gross margin.
Analyst sentiment is positive. Northland raised the price target to $50, citing a valuation disconnect from fundamentals and strong FY26 revenue and EPS estimates. Morgan Stanley increased the price target to $36, highlighting intact fundamentals and low valuation premiums in the EU Pharmaceuticals sector.
